Stocktoria
ENDRA Life Sciences Inc. NDRA
Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 2017-06-28
ENDRA Life Sciences Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $1.8M | $3.2M | $5.0M | $6.6M | $5.5M |
| Operating income | -$5.8M | -$10.8M | -$10.5M | -$13.2M | -$11.5M |
| Income tax | — | $0 | $0 | $0 | $0 |
| Net income | -$7.0M | -$11.5M | -$10.1M | -$13.2M | -$11.2M |
| EPS (diluted) | $-8.93 | $-56.94 | $-2766.85 | — | — |
| Operating cash flow | -$5.2M | -$7.4M | -$9.5M | -$12.8M | -$11.1M |
| Free cash flow | -$5.2M | -$7.4M | -$9.6M | -$13.0M | -$11.2M |
| Cash & equivalents | — | — | — | $4.9M | $9.5M |
| Inventory | $0 | $0 | $2.6M | $2.6M | $1.3M |
| Total assets | $3.9M | $4.5M | $6.8M | $9.3M | $12.9M |
| Total liabilities | $1.6M | $1.9M | $1.1M | $2.1M | $2.1M |
| Shareholders' equity | $2.3M | $2.6M | $5.7M | $7.2M | $10.8M |
Source: SEC EDGAR filings · CIK 0001681682 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.